Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months Arcus Biosciences reports 26.7-month median survival and 59% response rate in Phase 2 cancer study with domvanalimab combination therapy.
How Arcus Biosciences Aims To Take On Merck In Cancer Treatment Shares climbed Tuesday as enthusiasm grows for the biotech company's experimental cancer drug.
Why Is Arcus Biosciences Stock Trading Higher On Monday? Arcus Biosciences reports casdatifan monotherapy data in renal cancer, showing a 35% response rate and median progression-free survival not yet reached.
Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus On CNBC's Mad Money Lightning Round, Jim Cramer endorsed buying Uranium Energy and called Arcus Biosciences a speculative play.
Gilead Lifts Annual Outlook As Yeztugo Launch Nears Gilead raised its 2025 earnings and sales outlook after posting better-than-expected Q2 results, led by strong HIV and oncology drug sales.
Arcus Biosciences Shares Are Down Today: What's Going On? Arcus Biosciences Inc. (
NYSE: RCUS ) shares are trading lower Tuesday after the company announced a $150 million common stock offering.
